[Thrombolytic revascularization in acute myocardial infarct].

G. Mattioli

1986-09-01

Abstract:

What problem does this paper attempt to address?

Studing of the Special Problems in Thrombolysis Cure of Acute Myocardial Infarction

徐秋萍,郭丰,张舸,平玉坤,丁晨彦,张烨斐

DOI: https://doi.org/10.3969/j.issn.1002-1949.2001.07.008

2001-01-01

Abstract:Objective The aim of this study is to discuss some special problems of thrombolysis in the acute myocardial infarction (AMI)patients and to reduce the complications of thrombolysis.Methods The patients were diveded into several groups according to the administration of lidocain,urokinase and rt-PA.The symptoms of transient hypotension,fatal arrhythmia,heart failure,bleeding and reinfarction were observed.Results The incidence of transient hypotension was high in the urokinase group( P 0 01).The incidence of heart failure increased in the lidocain group.The incidence of fatal arrhythmia did not have significant difference between the lidocain group and the non-lidocain group.Conclusion The occurrence of transient hypotension may be related with allergic reaction,lidocain can't effectively prevent the occurrence of fatal arrhythmia.
Thrombolysis for acute ischaemic stroke: current status and future perspectives

Georgios Tsivgoulis,Aristeidis H Katsanos,Else Charlotte Sandset,Guillaume Turc,Thanh N Nguyen,Andrew Bivard,Urs Fischer,Pooja Khatri

DOI: https://doi.org/10.1016/S1474-4422(22)00519-1

Abstract:Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic reperfusion with an improved safety profile, increased efficacy, and convenient delivery. Tenecteplase has emerged as a potential alternative thrombolytic agent that might be preferred over alteplase because of its ease of administration and reported efficacy in patients with large vessel occlusion. Ongoing research efforts are also looking at potential improvements in recanalisation with the use of adjunct therapies to intravenous thrombolysis. New treatment strategies are also emerging that aim to reduce the risk of vessel reocclusion after intravenous thrombolysis administration. Other research endeavors are looking at the use of intra-arterial thrombolysis after mechanical thrombectomy to induce tissue reperfusion. The growing implementation of mobile stroke units and advanced neuroimaging could boost the number of patients who can receive intravenous thrombolysis by shortening onset-to-treatment times and identifying patients with salvageable penumbra. Continued improvements in this area will be essential to facilitate the ongoing research endeavors and to improve delivery of new interventions.
Intra-arterial Thrombolysis for Acute Cerebral Infarction

Wen-Bin Zhu,Yun Xu

DOI: https://doi.org/10.3760/cma.j.issn.1673-4165.2007.10.005

2007-01-01

Abstract:The intra-arterial thrombolysis is one of the most effective approaches in salvaging brain ischemic penumbra and treating acute cerebral infarction.However,because of the limita- tions of short time windows for treatment,intracerebral hemorrhage after thrombolysis and reocclusion,more clinical studies are needed before this technique is widely developed and applied.
Safety and efficacy of low-dose rt-PA with tirofiban to treat acute non-cardiogenic stroke: a single-center randomized controlled study

DOI: https://doi.org/10.1186/s12883-022-02808-w

2022-07-28

BMC Neurology

Abstract:The recanalization rate after intravenous thrombolysis (IVT) is not enough and there is still the possibility of re-occlusion. We aim to investigate the effectiveness and safety of infusing tirofiban after IVT.

clinical neurology
Intra-Arterial Thrombolytic Therapy for Acute Ischemic Stroke

Hua-Jun Zhang,Ren-Liang Zhang,Ge-Lin Xu,Xin-Feng Liu

DOI: https://doi.org/10.3760/cma.j.issn.1673-4165.2006.09.004

2006-01-01

Abstract:In recent years, multicenter studies have confirmed that intra-arterial thrombolysis is an effective approach in the treatment of acute cerebral infarction. This article reviews the study status quo of the time window, pretreatment assessment, and selection of patients and drugs for intra-arterial thrombolysis.
Improving Stroke Treatment and Outcomes With Mobile Stroke Units

Kristi G. Bache,James C. Grotta

DOI: https://doi.org/10.1001/jama.2020.25832

IF: 11.816

2021-02-02

JAMA

Abstract:Systemic thrombolysis with tissue plasminogen activator (tPA) improves outcome in patients with acute ischemic stroke. Twenty-five years of clinical research and experience have demonstrated that the sooner tPA is administered, the better the clinical outcomes.<sup><a class="ref-link section-jump-link" href="#jed200120r1">1</a></sup> Five years ago, clinical trials demonstrating that endovascular thrombectomy can substantially improve outcomes for patients with large vessel occlusions further expanded acute ischemic stroke treatment.<sup><a class="ref-link section-jump-link" href="#jed200120r2">2</a></sup> Taken together, these therapies provide important treatment options for clinicians, significant reduction in disability for patients, and reduced long-term costs for health care systems.
Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventricular function after acute myocardial infarction?

Luciano Agati,Stefania Funaro,Mariapina Madonna,Gennaro Sardella,Barbara Garramone,Leonarda Galiuto

DOI: https://doi.org/10.1016/j.ahj.2007.03.028

Abstract:Background: Recent data show that percutaneous coronary intervention (PCI) in patients with stable postthrombolytic ST-segment elevation myocardial infarction (STEMI) is better than no PCI or ischemia-guided PCI. These results still have to find a pathophysiologic explanation. We hypothesized that complete mechanical recanalization of infarct-related artery improves clinical benefits of thrombolysis as a result of more preserved and better perfused coronary microcirculation. To test this hypothesis, we studied a selected STEMI population presenting very early after symptom onset in whom successful infarct-related artery reperfusion was obtained by thrombolysis followed or not by elective PCI within 24 hours, and we compared these 2 groups with those underwent primary PCI. Methods: This study analyzed 96 patients with STEMI randomized within 3 hours from symptom onset to primary PCI (group A, n = 36), tenecteplase followed within 24 hours by PCI (group B, n = 30), or to tenecteplase alone (group C, n = 30). Microvascular perfusion was assessed by myocardial contrast echocardiography. Regional contrast score, endocardial length and area of contrast defect on day 2 (T1) and at predischarge (T2), left ventricular end-diastolic volume, regional wall motion score, extent of wall motion abnormalities, and ejection fraction at T1, T2, and at 3 months' follow-up were calculated. Results: Baseline clinical and angiographic characteristics were not statistically different between groups. The extent of microvascular damage and of myocardial salvage was similar in primary PCI-treated or in invasively treated patients after lytic administration. Conversely, group C patients, although treated very early with fibrinolytic therapy, showed higher extent of microvascular damage and infarct size and a more depressed left ventricular function after reperfusion and at follow-up. Conclusions: Our data suggest that early PCI after lysis is more effective in preserving myocardial perfusion and function than lysis alone and may be a helpful alternative when primary PCI is not available.
Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution.

R. Weibel,J. Stokes,E. Buynak,J. Whitman,M. B. Leagus,M. Hilleman

DOI: https://doi.org/10.1001/JAMA.1968.03140340024005

1968-08-19

Abstract:Duck embryo cell culture rubella virus vaccines prepared with the HPV-77 (Meyer-Parkman) and the Merck (B-level attenuation) strains of virus were evaluated in a large-scale family study in the open community and in an institution. Of 265 initially seronegative children vaccinated with the HPV-77 virus in duck embryo cell culture, 97% responded serologically with a geometric mean hemagglutination-inhibiting (HI) titer of 1:53.2. There was no apparent clinical illness and no serologic evidence for contact spread to 262 susceptible siblings or to 34 maternal contacts. The performance of the Merck B-level vaccine in duck embryo cell culture in the smaller institutional study was essentially the same as that of the HPV-77 except that the mean HI titer was almost three times as great (1:148.3). Both vaccines proved safe and efficacious in children, and community studies are in progress in larger numbers of persons.
Endovascular Administration after Intravenous Infusion of Thrombolytic Agents for the Treatment of Patients with Acute Ischemic Strokes

Jose I. Suarez,Osama O. Zaidat,Jeffrey L. Sunshine,Robert Tarr,Warren R. Selman,Dennis Landis,Dennis M.D. Landis

DOI: https://doi.org/10.1097/00006123-200202000-00005

IF: 5.315

2002-02-01

Neurosurgery

Abstract:ABSTRACT OBJECTIVE To determine the feasibility of combined intravenous and intra-arterial thrombolytic therapy for acute ischemic strokes and to evaluate its associated risks, using magnetic resonance imaging as a triage tool. Intravenous treatment followed by intra-arterial infusion may increase the rate of recanalization and lead to better clinical results, with reduced frequency of intracranial hemorrhage. METHODS Our Brain Attack Team evaluated patients who presented within 3 hours after symptom onset. Patients who did not demonstrate improvement and exhibited no evidence of intracranial hemorrhage on head computed tomographic scans were treated with intravenously administered recombinant tissue plasminogen activator (0.6 mg/kg) and underwent emergency magnetic resonance imaging of the head. T2-weighted turbo-gradient and spin echo and echo-planar diffusion- and perfusion-weighted imaging scans were obtained. Patients with evidence of imaging abnormalities indicating acute cortical infarction underwent cerebral angiography. After determination of vessel occlusion, intra-arterially administered urokinase (up to 750,000 units) or intra-arterially administered recombinant tissue plasminogen activator (maximal dose, 0.3 mg/kg) was used to achieve recanalization. RESULTS We treated 45 patients with this protocol. The mean age was 67 ± 13 years, and 58% of the patients were women. There was a significant improvement in National Institutes of Health Stroke Scale scores after treatment. There was good correlation between abnormal perfusion-weighted imaging findings and cerebral angiographic findings (complete vessel occlusion). The incidence of symptomatic intracranial hemorrhage was 4.4% in this cohort. Seven patients died in the hospital, and the majority of survivors (77%) experienced good outcomes (Barthel index of ≥95) 3 months after treatment. CONCLUSION Our data demonstrate that this protocol is feasible and that combined intravenous and intra-arterial thrombolysis to treat acute ischemic strokes is sufficiently safe to warrant further evaluation.

surgery,clinical neurology
Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries

Georgios Tsivgoulis,Odysseas Kargiotis,Andrei V Alexandrov

DOI: https://doi.org/10.1080/14737175.2017.1347039

Abstract:Intravenous tissue-plasminogen activator (tPA) remains the only approved systemic reperfusion therapy suitable for most patients presenting timely with acute ischemic stroke. Accumulating real-word experience for over 20 years regarding tPA safety and effectiveness led to re-appraisal of original contraindications for intravenous thrombolysis (IVT). Areas covered: This narrative review focuses on fast yet appropriate selection of patients for safe administration of tPA per recently expanded indications. Novel strategies for rapid patient assessment will be discussed. The potential for mobile stroke units (MSU) that shorten onset-to-needle time and increase tPA treatment rates is addressed. The use of IVT in the era of non-vitamin K antagonist oral anticoagulants (NOACs) is highlighted. The continuing role of IVT in large vessel occlusion (LVO) patients eligible for mechanical thrombectomy (MT) is discussed with regards to 'drip and ship' vs. 'mothership' treatment paradigms. Promising studies of penumbral imaging to extend IVT beyond the 4.5-hour window and in wake-up strokes are summarized. Expert commentary: This review provides an update on the role of IVT in specific conditions originally considered tPA contraindications. Novel practice challenges including NOAC's, MSU proliferation and bridging therapy (IVT&MT) for LVO patients, and the potential extension of IVT time-window using penumbral imaging are emerging as safe and potentially effective IVT applications.
The Changing Landscape of Intravenous Thrombolysis for Acute Ischaemic Stroke

Jack Donaldson,Joel Winders,Yassar Alamri,Dhara Knight,Teddy Y. Wu

DOI: https://doi.org/10.3390/jcm13195826

IF: 3.9

2024-09-30

Journal of Clinical Medicine

Abstract:Intravenous thrombolysis remains the most accessible and effective reperfusion therapy available to patients with acute ischaemic stroke. Treatment with intravenous thrombolysis improves the odds of favourable functional outcome with the unacceptably low risk of haemorrhagic complications. Even in the current era of endovascular thrombectomy, intravenous thrombolysis remains the backbone of acute stroke treatment due to its accessibility and relative ease of administration. Since intravenous alteplase was first approved for acute ischaemic stroke in the mid 1990s, there have been significant advances in expanding the indication and time window for treatment, in addition to transitioning towards tenecteplase use for stroke thrombolysis. In this review, we will provide a narrative on the use of thrombolysis in acute ischaemic stroke including an up-to-date discussion on recent advances in thrombolytic therapy.

medicine, general & internal
Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion

Stefan Straub,R. Seitz,V. Jovanovic,H. Wittsack,M. Siebler,U. Junghans

DOI: https://doi.org/10.1161/01.STR.0000117094.41638.EE

IF: 10.17

2004-03-01

Stroke

Abstract:Background and Purpose— In acute ischemic stroke, thrombolytic treatment with recombinant tissue plasminogen activator (rtPA) is limited by a concomitant activation of the coagulatory system, leading to incomplete or delayed reperfusion, microcirculatory disturbances, or even repeated vessel occlusions. Our pilot study sought to assess the therapeutic potential of a new treatment strategy combining rtPA at reduced dosages with a platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitory agent in acute middle cerebral artery occlusion. Methods— Nineteen patients suffering from acute middle cerebral artery occlusion (Thrombolysis in Myocardial Infarction [TIMI] flow grade 0 to 1) underwent combined intravenous thrombolytic treatment using rtPA at reduced dosages and the GPIIb/IIIa antagonist tirofiban. Stroke MRI (diffusion- and perfusion-weighted imaging) and MR angiography were performed at baseline and between days 1 and 2 after treatment. Clinical scores (National Institutes of Health Stroke Scale and modified Rankin Scale) were assessed at baseline and after 1 week. Results— Middle cerebral artery recanalization (TIMI flow grade 2 and 3) occurred in 13 of 19 patients (68%). The ischemic lesion on follow-up MRI was significantly smaller in patients with recanalization compared with those without recanalization (P =0.001). Only patients with recanalization improved neurologically (P <0.001). Because no symptomatic hemorrhage was observed, the power of our study to detect a symptomatic bleeding rate of ≥8% was at least 80%. Conclusions— Combined thrombolysis with a GPIIb/IIIa antagonist and rtPA at reduced dosages is promising but cannot be recommended for general use before prospective randomized clinical trials are completed.

Medicine
Safety and efficacy of reperfusion therapies in acute ischemic stroke related to left ventricular thrombus: A retrospective cohort study

P. Clottes,T. Bochaton,L. Mechtouff,L. Derex,T.-H. Cho,J. Fontaine,L. Rascle,Y. Berthezène,C. Amaz,H. Thibault,C. Bergerot,N. Nighoghossian,E. Ong

DOI: https://doi.org/10.1016/j.neurol.2023.12.009

IF: 4.313

2024-03-03

Revue Neurologique

Abstract:Background Left ventricular thrombus (LVT) is a source of cardiogenic embolic stroke. Conflicting data exist in the literature regarding the utilization of intravenous thrombolysis (IVT) at the acute phase of stroke in presence of LVT. We sought to assess the efficacy and safety of reperfusion therapies (IVT and/or thrombectomy) in patients with LVT. Methods We retrospectively analyzed patients with acute ischemic stroke and proven LVT and divided them in two groups: an intervention group with patients treated by reperfusion therapies and a control group with untreated patients. Results Between 2009 and 2021, 3890 patients were treated by reperfusion therapies in the Lyon stroke center, 33 of whom (0.9%) had LVT. We identified 27 control patients. There were more embolic recurrences at six months in the intervention group than in the control group (nine recurrences versus three, P = 0.03, OR = 13.56, 95% CI [1.5;195]). Only two early embolic recurrences (< 24 h) occurred, both in the IVT group. There was a 4.8-fold decrease in the median NIHSS score between baseline and 24 h follow-up in the intervention group ( P < 0.0001), and the two groups exhibited similar six-month mortality. At stroke onset, cardiopathy was known in 70% of patients, while LVT was known in 30%. Conclusion Acute reperfusion therapies seem to be effective in the context of stroke in patients with LVT. However, further studies are needed to support the hypothesis that stroke recurrence might be related to the use of IVT.

clinical neurology
Wake-up stroke and CT perfusion: effectiveness and safety of reperfusion therapy

Paola Caruso,Marcello Naccarato,Giovanni Furlanis,Miloš Ajčević,Lara Stragapede,Mariana Ridolfi,Paola Polverino,Maja Ukmar,Paolo Manganotti

DOI: https://doi.org/10.1007/s10072-018-3486-z

2018-07-10

Neurological Sciences

Abstract:ObjectiveIschemic stroke is a neuroemergency condition highly treatable with thrombolysis and thrombectomy. Recently, observational studies have brought insights into clinical and imaging characteristics of wake-up stroke, which interested up to 25% of ischemic stroke patients. In clinical practice, wake-up strokes are usually not considered for reperfusion therapy. The aim of this study was to investigate the use CT perfusion imaging in patients with wake-up stroke and to assess the effect of neuroimaging information provided by CT perfusion maps on the efficacy and safety of thrombolysis and thrombectomy.Patients and methodWe studied 22 wake-up stroke (WUS) patients (13F/9M mean age) who underwent reperfusion therapy after the eligibility assessed by the CT perfusion imaging (< 50% core-to-penumbra ratio and negative CT perfusion).ResultsMean National Institutes of Health Stroke Scale (NIHSS) was 8.1 ± 4.9 at admission while 3.3 ± 5.1 at discharge, significantly different from admission (p < 0.001). As many as ten patients had mRS lower than 3 at discharge. Intracranial hemorrhage occurred in five patients and caused symptoms worsening only in two patients (decrease of NIHSS score of 4 points) of which one patient died.ConclusionThe main finding of this study is that wake-up stroke with adequate selection by CT perfusion may benefit reperfusion treatment.

neurosciences,clinical neurology
Thrombectomy in Stroke Patients With Low Alberta Stroke Program Early Computed Tomography ...

Sameh Samir Elawady,Brian Fabian Saway,Hidetoshi Matsukawa,Kazutaka Uchida,Steven Lin,Ilko Maier,Pascal Jabbour,Joon-Tae Kim,Stacey Quintero Wolfe,Ansaar Rai,Robert M. Starke,Marios-Nikos Psychogios,Edgar A Samaniego,Adam Arthur,Shinichi Yoshimura,Hugo Cuellar,Jonathan A. Grossberg,Ali Alawieh,Daniele G. Romano,Omar Tanweer,Justin Mascitelli,Isabel Fragata,Adam Polifka,Joshua Osbun,Roberto Crosa,Charles Matouk,Min S. Park,Michael R. Levitt,Waleed Brinjikji,Mark Moss,Travis Dumont,Richard Williamson,Pedro Navia,Peter Kan,Reade De Leacy,Shakeel Chowdhry,Mohamad Ezzeldin,Alejandro M. Spiotta,Sami Al Kasab,on behalf of the STAR Collaborators

DOI: https://doi.org/10.5853/jos.2023.02292

2024-03-14

Journal of Stroke

Abstract:Background and Purpose Outcomes following mechanical thrombectomy (MT) are strongly correlated with successful recanalization, traditionally defined as modified Thrombolysis in Cerebral Infarction (mTICI)

peripheral vascular disease,clinical neurology
Liberal senators assail consumer safety bill

L. Eggertson

DOI: https://doi.org/10.1503/cmaj.109-3131

2010-02-09

Canadian Medical Association Journal

Abstract:The federal government’s new consumer safety legislation is a step closer to becoming law after Liberal amendments designed to check the powers of Health Canada inspectors were defeated in the Senate. The Senate voted 44–42 on Dec. 9, 2009, to pass Bill C–6, the Canada Consumer Product Safety
Safety and Efficacy of Low-Dose Tirofiban Combined With Intravenous Thrombolysis and Mechanical Thrombectomy in Acute Ischemic Stroke: A Matched-Control Analysis From a Nationwide Registry

Gaoting Ma,Shuo Li,Baixue Jia,Dapeng Mo,Ning Ma,Feng Gao,Xiaochuan Huo,Gang Luo,Anxin Wang,Yuesong Pan,Ligang Song,Xuan Sun,Xuelei Zhang,Liqiang Gui,Cunfeng Song,Ya Peng,Jin Wu,Shijun Zhao,Junfeng Zhao,Zhiming Zhou,Zhongrong Miao

DOI: https://doi.org/10.3389/fneur.2021.666919

IF: 3.4

2021-06-10

Frontiers in Neurology

Abstract:Purpose: Tirofiban administration to acute ischemic stroke patients undergoing mechanical thrombectomy with preceding intravenous thrombolysis remains controversial. The aim of the current study was to evaluate the safety and efficacy of low-dose tirofiban during mechanical thrombectomy in patients with preceding intravenous thrombolysis. Methods: Patients with acute ischemic stroke undergoing mechanical thrombectomy and preceding intravenous thrombolysis were derived from “ANGEL-ACT,” a multicenter, prospective registry study. The patients were dichotomized into tirofiban and non-tirofiban groups based on whether tirofiban was administered. Propensity score matching was used to minimize case bias. The primary safety endpoint was symptomatic intracerebral hemorrhage (sICH), defined as an intracerebral hemorrhage (ICH) associated with clinical deterioration as determined by the Heidelberg Bleeding Classification. All ICHs and hemorrhage types were recorded. Clinical outcomes included successful recanalization, dramatic clinical improvement, functional independence, and mortality at the 3-month follow-up timepoint. Successful recanalization was defined as a modified Thrombolysis in Cerebral Ischemia score of 2b or 3. Dramatic clinical improvement at 24 h was defined as a reduction in NIH stroke score of ≥10 points compared with admission, or a score ≤1. Functional independence was defined as a Modified Rankin Scale (mRS) score of 0–2 at 3-months. Results: The study included 201 patients, 81 in the tirofiban group and 120 in the non-tirofiban group, and each group included 68 patients after propensity score matching. Of the 201 patients, 52 (25.9%) suffered ICH, 15 (7.5%) suffered sICH, and 18 (9.0%) died within 3-months. The median mRS was 3 (0–4), 99 (49.3%) achieved functional independence. There were no statistically significant differences in safety outcomes, efficacy outcomes on successful recanalization, dramatic clinical improvement, or 3-month mRS between the tirofiban and non-tirofiban groups (all p > 0.05). Similar results were obtained after propensity score matching. Conclusion: In acute ischemic stroke patients who underwent mechanical thrombectomy and preceding intravenous thrombolysis, low-dose tirofiban was not associated with increased risk of sICH or ICH. Further randomized clinical trials are needed to confirm the effects of tirofiban in patients undergoing bridging therapy.

neurosciences,clinical neurology
Abstract TMP86: Effects of Tenecteplase versus Alteplase in Stroke Patients With Large Vessel Occlusions Who Achieve Full Recanalization

Aron Gedansky,Thomas Patterson,Gabor Toth

DOI: https://doi.org/10.1161/str.55.suppl_1.tmp86

IF: 10.17

2024-02-01

Stroke

Abstract:Introduction: Tenecteplase improves reperfusion and functional outcomes in stroke patients with large vessel occlusion. TNK is more specific for fibrin than TPA, however, it is unclear if this effect could increase efficacy of mechanical thrombectomy (MT). We aimed to determine if TNK is associated with higher recanalization rates and better clinical outcomes than TPA in patients who undergo MT. Methods: Electronic medical record review of acute stroke patients with LVO, age over 18 years, who received both thrombolysis with either TNK or TPA, and underwent MT at a tertiary medical center from January 2017 to April 2023 was performed. Use of TPA was converted to TNK on 1/11/2022 per hospital policy. Number of passes and time to full recanalization (defined as TICI 3) were recorded. Primary outcome was mRS at 90 days. Secondary outcomes were NIHSS at 24 hours and at discharge. Primary safety outcome was parenchymal hematoma type 2 (PH2) intracerebral hemorrhage. A t-test was used to examine association between outcomes and thrombolysis type. Fischer’s exact test was used to determine differences in recanalization and hemorrhage rates. Results: Of the 284 patients included, 213 received TPA and 71 received TNK. Mean age was 68, and 50.0% were females. Forty-three patients (60.6%) who received TNK, and 96 patients (45.1%) who received TPA achieved TICI 3 score (P=0.028). There was no difference in time to recanalization (38.5 min versus 32 min, p=0.872), median number of passes (1 versus 1, p=0.934), median 90-day mRS (2 versus 1.5, p=0.434), or the rate of PH2 hemorrhage (0% versus 2.3%, p=0.336) for TNK vs TPA in patients with TICI 3 recanalization. Median NIHSS at presentation (18.0 versus 16.0, p=0.398), at 24 hours (8.0 versus 7.0, p=0.406), and at discharge (3.0 versus 4.0, p=0.383) were similar for all patients receiving TNK and TPA, respectively. Conclusions: In our retrospective analysis, TNK showed a higher rate of TICI 3 recanalization for patients with LVO, who both received thrombolysis and underwent MT. There was no difference between TNK and TPA for number of passes, time to recanalization, parenchymal hematoma rate, and clinical outcomes in patients who achieved TICI 3. Overall clinical outcomes were also similar, irrespective of recanalization grade.

peripheral vascular disease,clinical neurology
Safety and efficacy of mechanical thrombectomy for acute ischemic stroke with volume over 50 mL and significant perfusion mismatch

Douglas Gonsales,Eberval Gadelha Figueiredo,Joao Paulo Mota Telles,Pedro Aguilar-Salinas,Nima Amin Aghaebrahim,Eric Sauvageau,Saul Almeida da Silva,Ricardo A Hanel

DOI: https://doi.org/10.25259/SNI_365_2024

2024-08-30

Abstract:Background: This study aims to address the safety and efficacy of mechanical thrombectomy (MT) in acute ischemic stroke with an established infarction equal to or >50 mL with a significant difference between penumbra and established infarction detected by perfusion cerebral computed tomography (CT) with the Rapid® system. Methods: This was a retrospective case-control study. Patients diagnosed with established and extensive ischemic stroke, defined by an ischemic volume equal to or >50 mL on CT or magnetic resonance imaging perfusion using the RAPID® system, were examined. The intervention group received endovascular interventional treatment with or without recombinant tissue plasminogen activator (rt-PA) in addition to standard therapy, and the control group received conservative treatment with or without rt-PA plus standard therapy. Results: A total of 59 patients were enrolled, including 38 in the intervention group and 21 in the control group. Baseline characteristics were similar between groups. Patient National Institutes of Health Stroke Scale at discharge was significantly different between the control (median 30, interquartile range [IQR] 13) and intervention group (median 8, IQR 14) (P < 0.001). Modified Rankin scale (mRS) scores were significantly different at discharge between intervention (median mRS 2, IQR 3) and controls (median mRS 5, IQR 1) (P = 0.002). These mRS differences remained significant at 90 days, with median (IQR) values of 2 (2.75) and 5 (1), respectively (P < 0.001). Conclusion: MT is safe and effective for large-core ischemic strokes with significant perfusion mismatch, leading to better functional outcomes without significant complications compared to the best medical treatment.
MMI-MZI Polymer Thermo-Optic Switch With a High Refractive Index Contrast

A. Al-hetar,A. .. Mohammad,A. Supa’at,Z. Shamsan

DOI: https://doi.org/10.1109/JLT.2010.2098473

IF: 4.7

2011-01-15

Journal of Lightwave Technology

Abstract:The 2 x 2 MMI-MZI polymer thermo-optic switch in a high refractive index contrast (0.102) with a new structure design is realized. The fabrication was done using standard fabrication techniques such as coating, photolithography, and dry etching. A crosstalk level of dB has been achieved. Meanwhile, the extinction ratio of 28.6 dB has been achieved in this device. The polarization-dependent loss of 0.3 dB was measured at 1550 nm wavelength. In terms of wavelength dependency, the device shows a good performance within C-band wavelength with vacillation of the insertion loss value around 0.88 dB. The power consumption of 1.85 mW was measured to change the state of the switch from the cross to bar state. The measured switching time was 0.7 ms.

[Thrombolytic revascularization in acute myocardial infarct].

Studing of the Special Problems in Thrombolysis Cure of Acute Myocardial Infarction

Thrombolysis for acute ischaemic stroke: current status and future perspectives

Intra-arterial Thrombolysis for Acute Cerebral Infarction

Safety and efficacy of low-dose rt-PA with tirofiban to treat acute non-cardiogenic stroke: a single-center randomized controlled study

Intra-Arterial Thrombolytic Therapy for Acute Ischemic Stroke

Improving Stroke Treatment and Outcomes With Mobile Stroke Units

Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventricular function after acute myocardial infarction?

Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution.

Endovascular Administration after Intravenous Infusion of Thrombolytic Agents for the Treatment of Patients with Acute Ischemic Strokes

Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries

The Changing Landscape of Intravenous Thrombolysis for Acute Ischaemic Stroke

Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion

Safety and efficacy of reperfusion therapies in acute ischemic stroke related to left ventricular thrombus: A retrospective cohort study

Wake-up stroke and CT perfusion: effectiveness and safety of reperfusion therapy

Thrombectomy in Stroke Patients With Low Alberta Stroke Program Early Computed Tomography ...

Liberal senators assail consumer safety bill

Safety and Efficacy of Low-Dose Tirofiban Combined With Intravenous Thrombolysis and Mechanical Thrombectomy in Acute Ischemic Stroke: A Matched-Control Analysis From a Nationwide Registry

Abstract TMP86: Effects of Tenecteplase versus Alteplase in Stroke Patients With Large Vessel Occlusions Who Achieve Full Recanalization

Safety and efficacy of mechanical thrombectomy for acute ischemic stroke with volume over 50 mL and significant perfusion mismatch

MMI-MZI Polymer Thermo-Optic Switch With a High Refractive Index Contrast